Clinical trials: Primary
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Haemophilus Influenzae Type b
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate…
- Trial name
- NCT01000974
- Testing
- GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™
- Where
- 63 sites in United States
- Volunteers
- 4,003 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Primary Open Angle Glaucoma, Ocular Hypertension
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
- Trial name
- NCT05022004
- Testing
- Brinzolamide ophthalmic suspension, Azopt®
- Where
- 40 sites in India, Russia
- Volunteers
- 599 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Neoplasms, Ovarian Neoplasms
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and…
- Conditions
- Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
- Trial name
- NCT01279291
- Testing
- KHK2866, Gemcitabine and Carboplatin, paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Migraine
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine.
- Trial name
- NCT05399485
- Testing
- Rimegepant
- Where
- 44 sites in Japan
- Volunteers
- 496 people
- Sponsor
- Pfizer
Renal Transplantation
A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients
A study comparing the early withdrawal of steroids to long-term maintenance steroid therapy in Kidney Transplant Patients receiving Prograf and Cellcept
- Trial name
- NCT00650468
- Testing
- tacrolimus, CellCept, steroids (methylprednisone or prednisone)
- Where
- 29 sites in United States
- Volunteers
- 397 people
- Sponsor
- Astellas Pharma Inc
Eye Cancer, Primary Cancer
Suprachoroidal Administration in Subjects With Metastases to the Choroid
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
- Trial name
- NCT06643884
- Testing
- AU-011, SCS Microinjector, Laser
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aura Biosciences
Multiple System Atrophy
A Study of Lu AF82422 in Participants With Multiple System Atrophy
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Trial name
- AMULET (NCT05104476)
- Testing
- Lu AF82422
- Where
- 19 sites in United States, Japan
- Volunteers
- 64 people
- Sponsor
- H. Lundbeck A/S
Primary Open-angle Glaucoma
PRESERFLO® MicroShunt Extension Study
This prospective, concurrent controlled, open-label, multicenter study is designed to collect additional safety data through 5 years of follow-up for subjects randomized to either the treatment arm (PRESERFLO® MicroShunt with…
- Trial name
- NCT04333433
- Testing
- PRESERFLO® MicroShunt, Trabeculectomy
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 279 people
- Sponsor
- InnFocus Inc.
Bilateral Breast Augmentation
Evaluation of the Safety and Performance of SYMATESE AESTHETICS ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants in the Breast Augmentation
The purpose of this study is to collect clinical data to evaluate the safety and performance of ESTYME® MATRIX Round microtextured breast implants in patients who receive these silicone gel-filled implants as part of their breast…
- Trial name
- EMMA (NCT05336526)
- Testing
- ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
- Where
- 6 sites in France
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Symatese Aesthetics
Syncope, Syncope, Vasovagal
Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
The purpose of this study is to explore changes in patients' hemodynamic parameters during the Head-Up Tilt Test ("HUTT") and their timing with respect to onset of the Closed Loop Stimulation (CLS) pacing.
- Trial name
- BIO|Sync-HUTT (NCT06038708)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Biotronik SE & Co. KG
Ovarian Cancer, Primary Peritoneal Cancer
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
This is an open-label study of liposomal doxorubicin with or without volociximab for the treatment of subjects with advanced epithelial ovarian cancer or primary peritoneal cancer relapsed after prior therapy with…
- Trial name
- NCT00635193
- Testing
- M200 (Volociximab), Liposomal Doxorubicin
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 138 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Myelofibrosis
Individual Patient Compassionate Use of Fedratinib
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.
- Trial name
- NCT03723148
- Testing
- Oral Fedratinib
- Where
- United States
- Sponsor
- Celgene
Liver Cirrhosis, Biliary
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver…
- Trial name
- COBALT (NCT02308111)
- Testing
- Obeticholic Acid (OCA)
- Where
- 181 sites in United States, Argentina and 29 more
- Volunteers
- 334 people
- Sponsor
- Intercept Pharmaceuticals
Non-muscle Invasive Bladder Cancer
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of intravesical cis-urocanic acid in patients with primary or recurrent non-muscle invasive bladder cancer.
- Trial name
- NCT01458847
- Testing
- cis-UCA solution
- Where
- 2 sites in Finland
- Volunteers
- 12 people
- Sponsor
- BioCis Pharma Ltd
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with…
- Conditions
- Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00463385
- Testing
- Pomalidomide, Prednisone
- Where
- 11 sites in United States, Austria and 3 more
- Volunteers
- 88 people
- Sponsor
- Celgene
Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative
Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.
The objective of this study is to demonstrate the ability of the Hydrus Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.
- Conditions
- Primary Open Angle Glaucoma, Glaucoma, Open Angle, Pseudo-exfoliative, Cataract Unilateral Pending Extraction
- Trial name
- Hydrus II (NCT01818115)
- Testing
- Hydrus Implant, IOL placement
- Where
- 7 sites in Germany, Italy and 2 more
- Volunteers
- 100 people
- Sponsor
- Ivantis, Inc.
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2)
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
- Conditions
- Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
- Trial name
- PHYOX2 (NCT03847909)
- Testing
- DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
- Where
- 28 sites in United States, Australia and 13 more
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Hereditary Angioedema
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
- Trial name
- KONFIDENT-KID (NCT06467084)
- Testing
- KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.